Buscar
Congreso SOLACI
HomeCoronary diseaseChronic Ischemic cardiopathy

Chronic Ischemic cardiopathy

Ver Categoría

Chronic Ischemic cardiopathy

ULTIMATE III: Use of IVUS for Coronary De Novo Lesion Drug Coated Balloon Angioplasty

Percutaneous coronary intervention (PCI) with drug eluting stents (DES) can present limitations, especially in the form of...
solaci -
Ver más
Chronic Coronary Syndromes

Intravascular Lithotripsy: Outcomes and Trends in the Treatment of Calcified Coronary Lesions

Lately, the complexity of percutaneous coronary artery interventions (PCI) has seen an increase, mainly driven by the...
solaci -
Ver más
Chronic Coronary Syndromes

Predictors of DCB Failure in De Novo Lesions

Percutaneous coronary intervention (PCI) with drug coated balloons (DCB) is a viable alternative, especially in patients at...
solaci -
Ver más
Antiplatelet

Antiplatelet Treatment with Ticagrelor vs. Clopidogrel in Patients with Chronic Coronary Syndrome

Achieving rapid and maximum inhibition of platelet aggregation can reduce complications related to scheduled percutaneous coronary intervention...
solaci -
Ver más
Chronic Ischemic cardiopathy

Long Term Outcomes of Hyperemic Stenosis Resistance Index (HSR) in Patients with Stable Chronic Angina

The hyperemic stenosis resistance index (HSR) was introduced as a more complete hemodynamic severity indicator of a...
solaci -
Ver más
Chronic Ischemic cardiopathy

Pre-Catheterization Fast

It has been generally established that coronary procedures with local anesthesia and moderate sedation minimally require a...
solaci -
Ver más
Chronic Ischemic cardiopathy

REPLICA-EPICA 18 Registry: Using IVL in Calcified Coronary Lesions

The presence of calcification in the coronary arteries (CAC) remains the main challenge in the percutaneous treatment...
solaci -
Ver más
Chronic Coronary Syndromes

Is Intravascular Lithotripsy Equally Effective in All Coronary Calcification Patterns?

Coronary calcifications pose a complex challenge with a high incidence (25% of all angioplasties), thus implying difficult...
solaci -
Ver más

SOLACI es la organización de referencia del intervencionismo cardiovascular latinoamericano.

Últimas Noticias

TAVR in Small Annuli: What Valve Should We Use?

Dr. Carlos Fava - 0
One of the major challenges of severe aortic stenosis are patients with small aortic annuli, defined as ≤430 mm² aortic valve area. This condition...

Patients at High Risk of Bleeding After Coronary Angioplasty: Are Risk Assessment Tools ARC-HBR and PRECISE-DAPT Useful?

Dr. Andrés Rodríguez - 0
Patients undergoing coronary stenting typically receive dual antiplatelet therapy (DAPT) for 6 to 12 months, consisting of a P2Y12 receptor inhibitor and aspirin. While DAPT...

ACC 2025 | WARRIOR: Ischemia in Women with Non-Obstructive Coronary Artery Disease

Dr. Omar Tupayachi - 0
Approximately half of all women with symptomatic ischemia who undergo coronary angiography are found to have non-obstructive coronary artery disease ((ischemia and non-obstructive coronary...

Noticias Institucionales

April 9 – How to Apply for the SOLACI Research Grant 2025? Virtual Zoom Event

solaci - 0
The Latin American Society of Interventional Cardiology invites you to a new virtual event hosted by the SOLACI Research Department, aimed at clarifying doubts,...

Watch our event on Evidence and Controversies of Renal Denervation in 2025

solaci - 0
You can now watch our event, held in collaboration with Medtronic, titled "Evidence and Controversies of Renal Denervation in 2025." The event featured international experts...

March 26 – SOLACI Webinar: Evidence and Controversies in Renal Denervation in 2025

solaci - 0
The Latin American Society of Interventional Cardiology invites you to a new virtual event supported by Medtronic. On this occasion, we will hold a 60-minute...

Accesos

Adolfo Alsina 2653 · Piso 2H · CABA · Buenos Aires · Argentina · (5411) 4954 7173 · info@solaci.org · solaci.org · Términos de uso -Políticas de privacidad